Funding for this research was provided by:
Cancer Research UK (C11232/A23434)
Programme Grants for Applied Research (RP-PG-0109-10020)
Received: 1 May 2018
Accepted: 2 April 2019
First Online: 22 May 2019
Ethics approval and consent to participate
: Ethical approval for this trial was granted by East Midlands – Nottingham 1 Research Ethics Committee (NRES reference 17/EM/0327).Informed consent to participate in the study will be obtained from participants.
: Not applicable.
: On two occasions since 2008, TC has been paid to attend and present at symposia arranged by Pierre Fabre Laboratories (PFL); PFL is a manufacturer of nicotine replacement therapy.All other authors have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.